#NEWS: We're launching the Phase 1 study of BI 3034701, a potential first-in-class, triple agonist obesity treatment developed in our partnership with Gubra. Discover how we are advancing our comprehensive strategy at https://bit.ly/4blrbNu #CardioMetabolic #ResearchCollaboration #Innovation
Exciting times! Boehringer Ingelheim and Gubra have initiated a Phase 1 clinical trial (NCT06352437) for BI 3034701, a novel triple-agonist peptide with the potential to be a first-in-class treatment for obesity. Significant Need: Over one billion people worldwide suffer from obesity, a major risk factor for various chronic diseases. Promising Candidate: BI 3034701 targets key receptors for weight loss and could offer a next-generation approach to obesity management. Phase 1 Focus: This initial study will assess safety, tolerability, and pharmacokinetics of the drug in healthy volunteers and individuals with overweight/obesity. This collaboration marks another step towards Boehringer Ingelheim's goal of providing innovative solutions for patients with obesity and related cardiometabolic conditions
Unfortunately a blinded structure but could it be one of the modified peptides in WO2016066818? Also oddly, the trial does not come back in the NCBI "All Databases" search (slow indexing of CT.gov?)
Exciting news! Looking forward to seeing the progress of BI 3034701 in the Phase 1 study.
Best of luck!
Very exciting.
Congratulations!
Great milestone! Congrats to the team! 👏